Individual investors invested in Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) copped the brunt of last week's US$31m market cap decline
yahoo.com
news
2022-10-17 16:13:52

Every investor in Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) should be aware of the most powerful shareholder groups. We can see that individual investors own the lion's share in the company with 37% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

While insiders who own 21% came under pressure after market cap dropped to US$241m last week,individual investors took the most losses.

In the chart below, we zoom in on the different ownership groups of Brooklyn ImmunoTherapeutics.
